Celltrion plans to commercialize 22 biosimilars by 2030, expanding its global presence with robust sales growth driven by core biosimilars and new launches like subcutaneous infliximab.
Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as ...
Number 4: Regulatory experts and representatives from some of the top biosimilar manufacturers emphasized the importance of ...
Direct costs associated with IBD include ambulatory visits to gastroenterologists, emergency department visits, admissions ...
On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, ...
By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster ...
The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products could be reconsidered, suggesting they might be eligible for new drug ...
An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and ...
Panelists emphasized the need for transparency and policy reforms in pharmacy benefit management (PBM) to improve ...
In October, the GRx+Biosims conference included discussions on data transparency, artificial intelligence, and collaboration ...
Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback